Artiva Biotherapeutics Common Stock Statistics
Share Statistics
Artiva Biotherapeutics Common Stock has 26.47M shares outstanding. The number of shares has increased by null% in one year.
| Shares Outstanding | 26.47M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | - |
| Failed to Deliver (FTD) Shares | 1.32K |
| FTD / Avg. Volume | 1.01% |
Short Selling Information
The latest short interest is 908.53K, so 3.74% of the outstanding shares have been sold short.
| Short Interest | 908.53K |
| Short % of Shares Out | 3.74% |
| Short % of Float | 22.59% |
| Short Ratio (days to cover) | 11.75 |
Valuation Ratios
The PE ratio is -4.05 and the forward PE ratio is -3.79.
| PE Ratio | -4.05 |
| Forward PE | -3.79 |
| PS Ratio | 3.35 |
| Forward PS | 3.7 |
| PB Ratio | -0.69 |
| P/FCF Ratio | -2.21 |
| PEG Ratio | n/a |
Enterprise Valuation
Artiva Biotherapeutics Inc. Common Stock has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 6.53, with a Debt / Equity ratio of 0.
| Current Ratio | 6.53 |
| Quick Ratio | 6.53 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is 0.17% and return on capital (ROIC) is 21.19%.
| Return on Equity (ROE) | 0.17% |
| Return on Assets (ROA) | -0.26% |
| Return on Capital (ROIC) | 21.19% |
| Revenue Per Employee | 408.44K |
| Profits Per Employee | -337.76K |
| Employee Count | 82 |
| Asset Turnover | 0.32 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 72.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is 0, so Artiva Biotherapeutics Common Stock's price volatility has been lower than the market average.
| Beta | 0 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | 12.22 |
| 200-Day Moving Average | null |
| Relative Strength Index (RSI) | 40.98 |
| Average Volume (20 Days) | 131.14K |
Income Statement
In the last 12 months, Artiva Biotherapeutics Common Stock had revenue of $33.49M and earned -$27.70M in profits. Earnings per share was $-2.96.
| Revenue | 33.49M |
| Gross Profit | 33.49M |
| Operating Income | -30.67M |
| Net Income | -27.70M |
| EBITDA | -28.41M |
| EBIT | -30.67M |
| Earnings Per Share (EPS) | -2.96 |
Balance Sheet
The company has $53.50M in cash and $16.91M in debt, giving a net cash position of $36.59M.
| Cash & Cash Equivalents | 53.50M |
| Total Debt | 16.91M |
| Net Cash | 36.59M |
| Retained Earnings | -181.31M |
| Total Assets | - |
| Working Capital | - |
Cash Flow
In the last 12 months, operating cash flow was -$47.43M and capital expenditures -$3.26M, giving a free cash flow of -$50.69M.
| Operating Cash Flow | -47.43M |
| Capital Expenditures | -3.26M |
| Free Cash Flow | -50.69M |
| FCF Per Share | -5.42 |
Margins
Gross margin is 100%, with operating and profit margins of -91.58% and -82.69%.
| Gross Margin | 100% |
| Operating Margin | -91.58% |
| Pretax Margin | -82.48% |
| Profit Margin | -82.69% |
| EBITDA Margin | -84.81% |
| EBIT Margin | -91.58% |
| FCF Margin | -151.34% |
Dividends & Yields
ARTV does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -28.14% |
| FCF Yield | -18.2% |
Analyst Forecast
The average price target for ARTV is $22, which is 109.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $22 |
| Price Target Difference | 109.1% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Scores
| Altman Z-Score | null |
| Piotroski F-Score | null |